Experimental model and subject details

HVTN 087 ({"type":"clinical-trial","attrs":{"text":"NCT01578889","term_id":"NCT01578889"}}NCT01578889) was a phase 1a HIV vaccine trial that tested intramuscular electroporation of a DNA vaccine with or without IL-12 adjuvant delivered as a plasmid at months 0, 1 and 3 followed by boosting with VSV-vectored HIV gag vaccine at month 6 (Elizaga et al., 2018; Li et al., 2017). Eight participants in this trial were selected for single cell analysis from Group 1 (no IL-12) and Group 3 (1000 mcg IL-12) based on sample availability. Participant demographics and group assignments are listed in Table S1. Blood was collected immediately before the first VSV-Gag administration and at sequential time points afterward. PBMC were isolated and cryopreserved as previously described (Bull et al., 2007).